Iaso Therapeutics Receives Phase I SBIR Grant from the National Cancer Institute

Iaso Therapeutics received a Phase I SBIR grant from the National Cancer Institute (NCI). The grant is to study the feasibility of developing a cancer vaccine against breast cancer including triple negative breast cancer after traditional frontline therapies. Iaso’s founder, Professor Xuefei Huang, has demonstrated the ability to generate an antibody response to tumor antigens that are protect mice from cancer when exposed to tumor cells. If successful, the work could lead to a Phase II grant from the NCI to pursue pre-clinical development of the cancer vaccine.